Head to Head Analysis: Inhibitor Therapeutics (OTCMKTS:INTI) & Elite Pharmaceuticals (OTCMKTS:ELTP)
companies based on the strength of their valuation, analyst recommendations, profitability, risk, institutional ownership, dividends and earnings. Inhibitor Therapeutics is a better stock than Elite Pharmaceuticals.
Which is the best stock among these two small-cap medical firms? We will compare these two companies based on their valuations, earnings, analyst ratings, institutional ownership and dividends, as well as risk.
Profitability
The table below compares Inhibitor Therapeutics with Elite Pharmaceuticals in terms of net margins, returns on equity and assets.
Net Margins
Return on Equity
Return on Assets
Inhibitor Therapeutics
N/A
-316.93%
398.92%
Elite Pharmaceuticals
21.76%
26.71%
15.50%
Inhibitor Therapeutics' beta is -0.46, which means that its stock price has 146% lower volatility than the S&P 500. Elite Pharmaceuticals, on the other hand, has a beta value of 0.21. This means that its stock is 79% more volatile than S&P 500.
Analyst Ratings
MarketBeat.com has reported on recent recommendations made by Inhibitor Pharmaceuticals and Elite Pharmaceuticals.
Sell Ratings
Hold Ratings
Buy Ratings
Strong Buy Ratings
Rating Score
Inhibitor Therapeutics
0
0
0
0
N/A
Elite Pharmaceuticals
0
0
0
0
N/A
Insider and Institutional Ownership
Institutional investors own 0.1% of Elite Pharmaceuticals' shares. Insiders own 4.6% of Inhibitor Therapeutics' shares. Insiders own 14.4% of Elite Pharmaceuticals. A stock with a high institutional ownership indicates that hedge funds, endowments and large money managers are confident the stock will perform better than the market in the long run.
Earnings and Value
This table compares Inhibitor Therapeutics with Elite Pharmaceuticals in terms of revenue, earnings per shares and valuation.
Gross Revenue
Price/Sales Ratio
Net Income
Earnings per Share
Price/Earnings ratio
Inhibitor Therapeutics
N/A
N/A
12:11 Million
N/A
N/A
Elite Pharmaceuticals
$32.26 Million
0.96
890 millions
$0.01
3.07
Inhibitor Therapeutics earns more, but has lower revenue, than Elite Pharmaceuticals.
You can read more about it here:
Elite Pharmaceuticals is superior to Inhibitor Therapeutics in 6 out of 8 factors.
Inhibitor Therapeutics
Get Rating
)
Inhibitor therapeutics, Inc. is engaged in the development and commercialization for cancer patients of therapeutics. It focuses on SUBAItraconazole a patented oral formulation of Itraconazole for the treatment of prostate and lungs cancers. The company was established on September 30, 1992, and has its headquarters in Tampa FL.
Elite Pharmaceuticals
Get Rating
)
Elite Pharmaceuticals, Inc. is engaged in the manufacture and development of opioid-based pharmacological products that are designed to deter abuse. It operates in two segments: Abbreviated New Drug Applications and New Drug Applications. The ANDA segment is composed of generic pharmaceuticals. The NDA segment consists of branded pharmaceuticals. MarketBeat.com offers a FREE daily email newsletter
.